| Recruiting | Pharmacokinetics, Bioequivalence, and Safety Study of Trimedat® 76,95 mg Orally Disintegrating Tablets and Tri Irritable Bowel Syndrome, Gallstone Disease, GERD | Phase 1 | 2025-11-06 |
| Recruiting | Study to Evaluate the Efficacy, Safety, and Tolerability of the Ingavirin Forte Capsules (Valenta Pharm JSC) a Influenza, Acute Respiratory Viral Infection | Phase 2 | 2025-10-24 |
| Recruiting | Efficacy and Safety of Ranquilon in Patients With Anxiety Disorders Due to Neurasthenia and Adjustment Disorde Anxiety, Neurasthenia, Adjustment Disorders | Phase 4 | 2025-01-13 |
| Recruiting | Study of the Safety, Tolerability, and Pharmacokinetic Profile of Ascending Doses of Ingavirin Forte, Capsules Influenza, Viral Respiratory Infection | Phase 1 | 2025-01-13 |
| Recruiting | Safety, Tolerability, and Pharmacokinetic Profile of Grammidin, a Metered Dose Topical Spray in Healthy Volunt Pharyngitis | Phase 1 | 2024-12-10 |
| Recruiting | Safety, Tolerability, and Pharmacokinetic Profile of Grammidin With Anesthetic, a Metered Dose Topical Spray i Pharyngitis | Phase 1 | 2024-12-09 |
| Recruiting | Study to Evaluate the Efficacy and Safety of Different Doses of Graminidin With Anesthetic, a Metered Dose Top Pharyngitis Acute, Pharyngitis, Nasopharyngitis | Phase 2 | 2024-11-14 |
| Recruiting | Efficacy, Safety, and Tolerability of 4-MUST Tablets in Chronic Cholecystitis and Biliary Dyskinesia Chronic Cholecystitis, Biliary Dyskinesia | Phase 2 | 2024-10-17 |
| Unknown | Pharmacokinetics and Bioequivalence of Aterixen 100 mg Tablets and Aterixen 100 mg Film-coated Tablets in Heal Viral Infection COVID-19 | N/A | 2024-06-15 |
| Recruiting | Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg/10 ml Oral Suspension and Rio Heartburn, Acid-dependent Diseases of the Gastrointestinal Tract, Symptomatic Treatment of Gastric and Duodenal Ulcers | N/A | 2024-04-25 |
| Unknown | Food Effect on the Bioavailability of 4-MUST, Tablets, 128 mg Cholecystitis | Phase 1 | 2024-03-19 |
| Completed | Pharmacokinetics and Bioequivalence of Doxylamine+Pyridoxine and Diclectin Under Fed Conditions in Healthy Vol Nausea | Phase 1 | 2024-02-27 |
| Recruiting | Efficacy and Safety of Vespireit, Prolonged-release Tablets, in Patients With Autonomic Dysfunction Syndrome A Vertigo, Autonomic Dysfunction | Phase 4 | 2024-01-24 |
| Unknown | Efficacy and Safety of Ingavirin®, Capsules, 60 mg, in Children With Influenza and Other Acute Respiratory Vir Influenza, Human, Acute Respiratory Infection, Common Cold | Phase 4 | 2023-12-19 |
| Unknown | Safety, Tolerability and Pharmacokinetics of 4-MUST, Tablets, 128 mg (Valenta Pharm JSC) During Single and Mul Cholecystitis | Phase 1 | 2023-12-04 |
| Recruiting | Efficacy and Safety of XC8, Film-coated Tablets, in Children With Acute Respiratory Viral Infections Acute Respiratory Infection | Phase 3 | 2023-12-04 |
| Completed | A Study of the Efficacy and Safety of Ranquilon Tablets in Patients With Anxiety in Neurasthenia and Adjustmen Anxiety, Neurasthenia, Adjustment Disorders | Phase 3 | 2022-10-12 |
| Completed | Pharmacokinetics and Bioequivalence of XC8 10 mg and 40 mg Tablets in Fasted Volunteers Influenza, Respiratory Viral Infection | N/A | 2022-08-22 |
| Completed | Pharmacokinetics and Bioequivalence of Doxylamine + Pyridoxine, Film-coated, Enteric-soluble Tablets, and Dicl Pregnancy Related, Nausea | N/A | 2022-08-18 |
| Completed | A Study to Evaluate the Safety and Efficacy of XC221 in Patients With Uncomplicated Influenza or Other Acute V Influenza, Respiratory Viral Infection | Phase 3 | 2022-08-05 |
| Completed | Efficacy and Safety of Dioxidin Versus Miramistin in Superficial Pyoderma Pyoderma | Phase 3 | 2022-07-19 |
| Completed | Efficacy and Safety of XC8, Film-coated Tablets, 40 mg in Patients With Dry Non-productive Cough Against Acute Common Cold, Acute Respiratory Infection, Influenza, Human | Phase 3 | 2022-05-23 |
| Completed | Safety and Pharmacokinetics of Dioxidin, Solution for Topical and External Use, 0.25 mg/ml and Dioxidin, Solut Infections | Phase 1 | 2022-05-04 |
| Completed | Pharmacokinetics and Bioequivalence of Molnupiravir, 200 mg Capsules and Lagevrio, 200 mg Capsules in Healthy Viral Infection, COVID-19 | N/A | 2022-04-22 |
| Completed | Study of the Effect of Food Intake on the Bioavailability of XC221 100 mg Tablets Healthy | Phase 1 | 2022-02-10 |
| Completed | Study of the Effect of Food Intake on the Bioavailability of XC8 10 mg Film-coated Tablets Healthy | Phase 1 | 2022-02-01 |
| Completed | Efficacy and Safety of Buspirone, Sustained-release Tablets, 15 mg in Patients With Autonomic Dysfunction Synd Vertigo, Autonomic Dysfunction | Phase 3 | 2022-01-28 |
| Completed | Efficacy and Safety of Ingavirin®, 90 mg Capsules in Patients With COVID-19 COVID-19 | Phase 3 | 2021-10-06 |
| Completed | A Study to Evaluate the Safety, Tolerability and Efficacy of XC221 in Patients With Uncomplicated Influenza or Influenza, Viral Respiratory Infection, Acute Viral Upper Respiratory Infections | Phase 2 | 2021-10-01 |
| Completed | Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory V Influenza, Human, Acute Respiratory Infection, Common Cold | Phase 3 | 2021-09-23 |
| Completed | Comparative Pharmacodynamics and Pharmacodynamics Equivalence of Antareit 800 mg Chewable Tablets and Riopan 8 Heartburn, Acid-dependent Diseases of the Gastrointestinal Tract, Symptomatic Treatment of Gastric and Duodenal Ulcers | N/A | 2021-07-07 |
| Completed | Efficacy and Safety of XC8, Film-coated Tablets, 10 mg in Patients With Dry Non-productive Cough Against Acute Common Cold, Acute Respiratory Infection, Influenza, Human | Phase 2 | 2021-04-26 |
| Completed | Efficacy and Safety Study of Ingavirin® to Treat Influenza and Other Acute Respiratory Viral Infections in Pat Common Cold, Influenza | Phase 3 | 2016-01-01 |
| Completed | Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Children Influenza, Human, Acute Respiratory Infection, Viral Infection | Phase 3 | 2014-08-01 |
| Completed | Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Patients Influenza, Human, Acute Respiratory Infection, Viral Infection | Phase 3 | 2012-01-01 |
| Completed | Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections Influenza, Human, Acute Respiratory Infection, Common Cold | Phase 3 | 2010-10-03 |
| Completed | Efficacy and Safety Study of Ingavirin® 90 mg Once Daily to Treat Influenza and Other Acute Viral Infections i Common Cold, Influenza, Human, Acute Respiratory Infection | Phase 4 | 2010-01-01 |